Health care researchers are increasingly endeavoring to incorporate data in clinical trials that demonstrate a health benefit for patients. One of the measurements that can capture this vital information is health-state utility, which reflects a patient鈥檚 rating of their current well-being compared to a 鈥減erfect鈥� health state. As such, health-state utility data provide a measurement of quality-of-life, which is part of a long-term calculation of treatment benefit. Health-state utility data are important inputs in cost-utility models that are used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Collection of health state utility data within the clinical trial offers a unique opportunity to directly capture key aspects of treatment benefit; however, careful planning is needed to ensure that these important measures are incorporated in the design of the clinical trial to collect high-quality data for economic models.
The Task Force identified five areas of guidance that will enable researchers to design an optimum utility measurement program within clinical studies. The guidance focused on these specific areas: 1) Early planning of health utility data collection within the research and development program2) Design of health utility data collection during protocol development for a planned clinical trial3) Design of prospective and cross-sectional observational studies for estimating health utility4) Use of alternative study types for health-state utility estimation5) Statistical analyses and reporting to maximize the value of patient-level health utility data for economic models
According to Sorrel E. Wolowacz, PhD, corresponding author, 鈥渃linical trials represent a valuable opportunity to gather health utility data. However, because most trials are designed chiefly to collect efficacy and safety data to support market approval (not to collect data for health economic models), an important opportunity to gather health utility data is often missed or problems can arise when applying data that has been collected in cost-utility models. Therefore, careful planning is needed early in the process to establish a well-thought out design for health-state utility collection in clinical studies. The Task Force recommendations are intended to help researchers to design the optimum program of utility measurement in clinical studies and to develop a strong scientific rationale for that design.鈥�
The complete Task Force Report can be found . ISPOR is also offering a new related to this topic鈥�Collecting Health-State Utility Estimates for Economic Models in Clinical Studies鈥攖hat will be offered for the first time on October 29 at the upcoming .
###
ABOUT ISPORThe International Society for Pharmacoeconomics and Outcomes Research () is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: | LinkedIn: | Twitter: (@ISPORorg) | YouTube: |Facebook:
ABOUT VALUE IN HEALTH (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of pharmacoeconomics and outcomes research to help health care leaders make evidence-based decisions. The journal鈥檚 2015 impact factor score is 3.824. Value in Health is ranked 3rd out of 74 journals in health policy and services (social sciences), 8th out of 87 journals in health care sciences and services, and 10th out of 344 journals in economics (social sciences). Value in Health is published bi-monthly and circulates to more than 10,000 readers around the world. Web: | Twitter: (@ISPORjournals)
RSS